About the study: 

Menopause occurs on average at the age of 51 years. By this time women do not produce sufficient estrogen or testosterone necessary for good bone health. As a result, most women experience progressive bone loss, increasing the risk of osteoporosis (weakened bone strength) and fragility fracture.›

Despite adequate estrogen replacement many women also experience loss of sexual desire and arousal after menopause.

There is some evidence that the addition of testosterone to estrogen replacement therapy might prevent bone loss and restore sexual function in women with early menopause, but further evidence from well conducted trials is still needed.

We invite you to participate in this study to determine whether a testosterone therapy approved for use in women in Australia prevents bone loss and improves sexual function in postmenopausal women, aged less than 55 years who are using estrogen replacement.

Participation involves up to 5 visits over 12 months with blood collection, and bone density scans at commencement and at 12 months

Researchers 

Women’s Health Research Program, Monash University

Ethics Approval

This study is approved by Monash University Human Research  Ethics Committee

Contact

To participate or for further information
Please contact:
Women’s Health Research Program
Monash University
Phone: (03) 99030827
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
The Women’s Health Research Program

Monash Study flyer 9.1.2023118.06 KB

[Ref: V 3 dated 9/1/2023]

About the study: 

This study aims to determine whether an approved testosterone therapy for women is effective in preventing bone loss and improving sexual function in women with early menopause who are taking the standard dose of oestrogen. Join and do your part to help advance breakthroughs in this clinical research.

Who can take part in this study?

In order to be eligible to participate in the study, you must meet all of the following:

• You are aged between 18 and 44
• You have experienced menopause OR had both ovaries removed before 45 years of age
• You have been on a stable dose of oestrogen replacement therapy (ERT) for at least 3 months.
• Your body mass index is between 18 and 38.

Who is unable to take part in this study?

Unfortunately, if you have a history of a known bone disease or another condition associated with osteoporosis, this study is not the right fit for you.

How long will the study take?

If you agree to take part, and the study is suitable for you, your participation in the study is expected to last up to 12 months. This may include:

• Screening period (2-4 weeks): 1 visit to the study centre
• Treatment period (12 months): Up to 4 visits to the study centre for up to 60-90 minutes at a time.
• Blood collection and bone density scans at the beginning and end of the trial.
• Some of these visits can be done by telehealth

Where are the study sites?

• The Women’s Health Research Program, Monash University 553 St Kilda Rd, Melbourne 3004 (lead centre),
• Monash University, Monash Health, 246 Clayton Rd, Clayton 3168
• The Keogh Institute of Medical Research 1st floor C Block QEII Medical Centre Hospital Avenue Nedlands WA 6009, Hospital Ave, Nedlands WA 6009

Learn more 

For more information and how to register go to 

Early Menopause Medical Study 
https://trials.evrima.com.au/early-menopause-medical-study

About the study: 

We are recruiting women across Australia who are under the age of 45 and are at high risk for ovarian cancer and planning a bilateral salpingo-oopherectamy (BSO) within the next 12 months, as well as women under the age of 45 who have undergone BSO in the past 12 months. 

This project is conducted via videoconferencing (all online) and involves interviews to assess mood and cognition.  

Lead researchers 

Associate Professor Caroline Gurvich (Clinical Neuropsychologist, Monash University)

Associate Professor Amanda Vincent (Endocrinologist, Monash Health and Monash University) 

Professor Martha Hickey (Professor of Obstetrics and Gynaecology, RWH and University of Melbourne).  

Ethics Approval

This research has approval from ethics committee (Alfred Health Ethics Committee and Monash University ethics committee) and is funded by The Centre for Research Excellence in Women's Health in Reproductive Life (CRE WHiRL) and the Women's Health Research Translation Network (WHRTN). 

Contact

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: 03 9076 5034

 

If you or your loved one are above the age of 40 and experiencing the following symptoms, you may be eligible to participate in a clinical trial investigating a potential new medication for perimenopausal women with depression:

Depressive symptoms:

• Feeling down or low all of the time
• Fatigue or lacking energy
• Thoughts of helplessness or worthlessness
• Change in appetite
• Trouble sleeping
• Difficulties in concentration
• Loss of interest in activities that were once enjoyable

Perimenopausal symptoms:

• Irregular periods more than 60 days apart but less than 365 days apart
• 4 or more hot flushes per day/night

If you are interested, please get in touch with one of our friendly research teams. Contact details of our lead doctors are as given below.

Study: Depressed with Perimenopausal Symptoms?587.47 KB

Meet the lead doctors: 

---

Epworth Clinic

Professor Paul Fitzgerald

Site Name: Epworth Centre for Innovation in Mental Health (ECIMH)

Address: 888 Toorak Road, Camberwell, VIC, 3124

Phone: (03) 9805 4363

Email: This email address is being protected from spambots. You need JavaScript enabled to view it. OR This email address is being protected from spambots. You need JavaScript enabled to view it. 

---

NeuroCentrix

Dr Peter Farnbach

Site Name: NeuroCentrix

Address: 1303 Heatherton Rd, Noble Park 3174

Phone: (03) 9546 0009

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.  

---

Monash University

Professor Jayashri Kulkarni

Site Name: MAPrc / Alfred Health

Address: Level 4, 607 St Kilda Road Melbourne, Victoria 3004

Phone: +61 3 9076 6564

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

COMMA (Core Outcome Set for Menopausal Symptoms) is inviting clinicians, researchers and women who have experienced menopause around the world to provide input on what symptoms should be measured in trials of treatments for menopausal symptoms. Clinical trials for menopausal symptoms have measured a wide range of different outcomes, making it difficult to compare treatments and limiting the relevance of these studies for clinical practice. COMMA will standardise this process by developing a “Core Outcome Set” of measures for future clinical trials.

Please complete this short survey to tell us what menopausal symptoms you believe are most important.  These responses will be used to develop a new Core Outcome Set reflecting the views of clinicians and consumers. Please also circulate the survey amongst your networks

COMMA is funded by the University of Melbourne and supported by menopause societies internationally and the leading journals in menopause.

The survey takes about 10 minutes and all those who complete the survey will be included in a draw for a $200 Westfield voucher.

The survey is now closed.

Originally published May 2019

Content updated January 2021

Description of Study

MonaLisa Touch^TM (MLT) is a new treatment for women with vulvovaginal symptoms that involves treatment of the vaginal lining with tiny pin-point laser applications with the aim of restoring the skin to a state similar to that prior to the menopause. At present, there is not enough evidence about the effectiveness of MonaLisa Touch^TM for it to be recommended as a medical treatment. It is currently expensive to access and there is no Medicare rebate available.

Researchers are currently running a clinical trial in Australia which will evaluate how effective MonaLisa Touch^TM is in treating postmenopausal vulvovaginal symptoms and provide high quality information to guide women with vulvovaginal symptoms as to their best treatment options.

Recruitment has now closed, and results will be available later in 2020.

For more information, please contact the GRACE Research group at the Royal Hospital for Women in Sydney:

Ethics Approval 

Department of Gynaecology, Royal Hospital for Women HREC ref no: 15/330

Investigator

Prof Jason Abbott

Contact details

This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone 0491 231 771

Note: This page is only available for viewing by registered members. Study pages, when accepted, will be available to the public.